ESSEA Working Groups

WG3: Testing how well screening instruments work in prospectively identifying cases.

Work Group 3 involves groups who are using screening instruments to prospectively identify cases of autism in infancy and the early years.

The first ever prospective screening study of autism was undertaken just over 10 years ago in the UK Since this time several other European scientists have developed novel screening instruments and tested their ability to identify cases at 14 months of age  Other groups in several European countries are engaged in studies testing the efficiency of screens to identify cases in nursery and preschool (Belgium, Israel) and clinical services (Italy, UK); as well in large population studies (Italy, Norway, The Netherlands).

The ESSEA COST Action will allow clinical scientists to compare and pool datasets to identify whether screens work differently in different communities. Exchange of information on screening studies and the emerging population estimates for the prevalence of autism that such studies also produce might identify real differences in prevalence or presentation that would raise fundamental questions regarding the epidemiology and clinical course of the disorder. The COST Action will lead to the production of harmonised clinical guidelines on early identification of autism.

Chair:  Ricardo Canal Bedia (Spain)
Co- Chair: Evald Saemundsen (Iceland)
Annika Melinder (Norway)
Bernadette Roge (France)
Emma van Daalen (Netherlands)
Filippo Muratori (Italy)
Irma Moilanen (Finland)
Mieke Dereu (Belgium)
Michele Noteradaeme (Germany)
Nada Pop-Jordanova (Former Yugoslav Republic of Macedonia)
Patricia Garcia-Primo (Spain)
Rafal Kawa (Poland)
Sanne Lemcke (Denmark)
Sigridur Jonsdottir (Iceland)
Synnve Scholberg (Norway)
Tatjana Zorcec (Former Yugoslav Republic of Macedonia)